Description
Growth Hormone Secretagogue Blend
(hGH Fragment 176–191 + Mod GRF 1-29 + Ipamorelin)
Contents (per vial):
- 6 mg hGH Fragment 176–191
- 3 mg ModGRF (1–29) (CJC-1295 without DAC)
- 3 mg Ipamorelin
Structural Characteristics:
This synergistic peptide formulation combines three growth hormone secretagogues with complementary actions:
- hGH Fragment 176–191 – a C-terminal fragment of hGH, modified to selectively promote lipolysis without increasing IGF-1.
- ModGRF (1–29) – a stabilized GHRH analog optimized for physiological GH pulse stimulation.
- Ipamorelin – a selective GHS-R1a (ghrelin receptor) agonist with minimal effect on cortisol or prolactin.
Mechanism of Action (Research Context):
Designed to emulate natural GH release patterns through dual stimulation of GHRH and ghrelin receptors, this blend supports research into:
- Lipolytic and metabolic regulation
- GH secretion dynamics and endocrine function
- Lean body mass and muscle preservation
- Combined upstream GH secretagogue pathways
Synthesis and Quality Control:
- Produced using solid-phase peptide synthesis (SPPS)
- HPLC-purified to ≥98%
- Verified by Mass Spectrometry (MS)
Product Details:
- Form: Lyophilized acetate salt blend
- Appearance: White to off-white powder
- Supplied in: 3mL sterile vial
Solubility & Reconstitution:
This product is highly sensitive to pH and oxygen exposure.
- For optimal reconstitution, use sterile bacteriostatic water with pH between 5.0–6.0
- Higher pH or prolonged air exposure may result in gelling or peptide aggregation
- Reconstituted solutions should be gently swirled; avoid vigorous shaking or aeration
Storage & Handling:
- Store lyophilized powder at –20°C, protected from light and moisture
- After reconstitution, refrigerate at 2–8°C for up to 30 days
- For long-term storage, aliquot and freeze at –20°C
- Avoid repeated freeze-thaw cycles or prolonged exposure to air
Disclaimer:
For research use only. Not for human or veterinary use. Not for diagnostic or therapeutic applications.
Reviews
There are no reviews yet.